(Q35951806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Richard B Lock

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Min H Kang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

3

Peter J Houghton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

12

John M Maris

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

14

Malcolm A Smith

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

2

E Anders Kolb

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

6

Stephen T Keir

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

7

Hernan Carol

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

13

Catherine Billups

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

5

Geoffrey Neale

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

11

C Patrick Reynolds

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Christopher L Morton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Doris Phelps

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

7 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

published in

Pediatric Blood & Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

1266-1274

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

22 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Flavopiridol in chronic lymphocytic leukemia: a concise review

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

A phase I study of flavopiridol and docetaxel.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

E2F: a link between the Rb tumor suppressor protein and viral oncoproteins

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Development of cell-cycle inhibitors for cancer therapy

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

The pediatric preclinical testing program: description of models and early testing results.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Chronic lymphocytic leukemia: a niche for flavopiridol?

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Proliferation of cancer cells despite CDK2 inhibition.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening

24 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FPBC.24073

Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349821

Guidelines for accurate EC50/IC50 estimation

14 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22315240

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/PBC.24073

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22315240%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

PubMed publication ID

22315240

1 reference